Acrivon Therapeutics, Inc.'s market cap is currently ―. The company's EPS TTM is $-2.88; its P/E ratio is -2.90; Acrivon Therapeutics, Inc. is scheduled to report earnings on August 9, 2024, and the estimated EPS forecast is $-0.60. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	-	-	$ 134.00K	-	$ 0.00
Gross Profit	-	-	$ 134.00K	-	-
EBIT	$ -19.27M	$ -13.91M	$ -12.76M	-	$ -9.57M
EBITDA	$ -19.85M	$ -14.48M	$ -13.79M	-	$ -9.46M
Net Income Common Stockholders	$ -19.25M	$ -13.91M	$ -12.76M	-	$ -9.20M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 127.46M	$ 150.95M	$ 120.21M	$ 127.75M	$ 76.82M
Total Assets	$ 138.26M	$ 160.05M	$ 170.20M	$ 181.23M	$ 87.71M
Total Debt	$ 4.64M	$ 4.60M	$ 4.79M	$ 4.96M	$ 5.14M
Net Debt	$ -122.81M	$ -146.35M	$ -115.43M	$ -122.79M	$ -71.69M
Total Liabilities	$ 17.07M	$ 10.87M	$ 9.73M	$ 10.75M	$ 133.33M
Stockholders Equity	$ 121.19M	$ 149.18M	$ 160.47M	$ 170.47M	$ -45.62M
Cash Flow	-
Free Cash Flow	$ -13.52M	$ -9.15M	$ -11.41M	$ -9.61M	$ -6.95M
Operating Cash Flow	$ -12.37M	$ -9.04M	$ -11.38M	$ -9.35M	$ -6.52M
Investing Cash Flow	$ 20.54M	$ 19.34M	$ 9.33M	$ -95.07M	$ -45.12M
Financing Cash Flow	$ -2.01M	$ 379.00K	-	$ 101.86M	$ -140.00K

Currency in USD

Acrivon Therapeutics, Inc. Earnings and Revenue History

Income Statement >

Acrivon Therapeutics, Inc. Debt to Assets

Balance Sheet >

Acrivon Therapeutics, Inc. Cash Flow

Cash Flow >

Acrivon Therapeutics, Inc. Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing